Brainsway

Developer of non-invasive treatment of brain disorders.

Maya TradingView

Market view

Stock chart

Coverage

Analyses on Brainsway (3)

June 25, 2026
June 25, 2026
1. BrainsWay SWIFT coverage reaches 57 million lives, and revenue depends on clinic installs
  Expanded SWIFT coverage improves BrainsWay's U.S. reimbursement route, but it does not prove revenue. Value will depend on clinic adoption, system utilization and conversion into revenue and margin.
May 13, 2026
May 13, 2026
1. Follow-up
  BrainsWay and the private options: strategic investments buy growth paths but reduce excess cash
  BrainsWay is using a profitable quarter to buy private growth options, but the first quarter already shows that they reduce excess cash before they provide a separate operating contribution.
2. BrainsWay in the first quarter: growth is profitable, collection is the next test
  BrainsWay opened 2026 with a quarter that proves real operating leverage: revenue grew 35%, operating income nearly reached the lower end of the 2026 margin target and RPO rose to $75 million. The test has moved from product adoption to quality of growth, mainly collection, cust…

Same sector

More companies in Medical Devices (6)

Sofwave Medical

Allmed Solution